Skip to content
DataLookout
Start free
Menu

NCT07898709

Evaluating SGLT2 Inhibitors for the Reduction of No-Reflow Phenomenon in Patients Undergoing PCI

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Incidence of angiographic no-reflow/impaired myocardial reperfusion
Timeframe: Periprocedural(At completion of PCI)

Secondary (1)

Incidence Contrast induced-Acute Kidney injury(CI-AKI)

Arms and interventions

Standard Care (Control)Active comparator

Patients with myocardial infarction undergoing PCI will receive standard of care pharmacological Treatment alone.

Standard Care (Control) + EmpagliflozinExperimental

Patients with myocardial infarction undergoing PCI will receive standard of care pharmacological Treatment in addition to empagliflozin orally as a single oral dose before PCI, followed by empagliflozin orally once daily for three days.

Standard Care (Control) + DapagliflozinExperimental

Patients with myocardial infarction undergoing PCI will receive standard of care pharmacological Treatment in addition to Dapagliflozin orally as a single oral dose before PCI, followed by empagliflozin orally once daily for three days.

Drugs: Empagliflozin (SGLT2i), dapagliflozin, Standard medical treatment

Sites

4 sites in 1 country